<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1321">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05143957</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 702843-CS4</org_study_id>
    <secondary_id>2021-003704-40</secondary_id>
    <nct_id>NCT05143957</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate IONIS-TMPRSS6-LRx (ISIS 702843) in Patients With Polycythemia Vera</brief_title>
  <official_title>A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy of IONIS-TMPRSS6-LRx in reducing&#xD;
      the frequency of phlebotomy and in improving quality of life assessments in participants with&#xD;
      polycythemia vera.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, multi-center, randomized, open-label study of IONIS-TMPRSS6-LRx in up to&#xD;
      40 participants with PD-PV. The study consists of 3 periods: 1) Screening Period: up to 7&#xD;
      weeks; 2) Treatment Period: 33 weeks + a 4-week post-last dose visit; 3) Post-treatment&#xD;
      Period: 13 weeks.&#xD;
&#xD;
      In the Treatment Period, study drug is given by subcutaneous (under the skin) injection(s).&#xD;
      There will be a total of 10 doses given over about 8 months.&#xD;
&#xD;
      Participants will be assigned to receive one of 2 Dosing Levels - a higher or a lower level,&#xD;
      with an equal chance of being assigned to either Dosing Level. All participants will receive&#xD;
      study drug; there is no placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the frequency of phlebotomy comparing Baseline with the last 20 weeks of the 37 week Treatment Period</measure>
    <time_frame>Week 17 to Week 37</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a reduction in the frequency of phlebotomy by ≥ 30%, ≥ 50%, ≥ 75% and ≥ 90% comparing Baseline with the last 20 weeks of the 37-week Treatment Period</measure>
    <time_frame>Week 17 to Week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Myeloproliferative Neoplasm Symptom Assessment Form-Total Symptom Score (MPN-SAF-TSS) From Baseline to Week 37</measure>
    <time_frame>Baseline up to Week 37</time_frame>
    <description>sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. The scores range from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be) for each item. The total score is the summation of all the individual scores (0-100 scale). A higher score indicates worse symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Phlebotomy Dependent Polycythemia Vera</condition>
  <arm_group>
    <arm_group_label>IONIS-TMPRSS6-LRx Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IONIS-TMPRSS6-LRx will be administered by SC injection every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IONIS-TMPRSS6-LRx Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IONIS-TMPRSS6-LRx will be administered by SC injection every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-TMPRSS6-LRx</intervention_name>
    <description>IONIS-TMPRSS6-LRx will be administered by SC injection.</description>
    <arm_group_label>IONIS-TMPRSS6-LRx Dose Level 1</arm_group_label>
    <arm_group_label>IONIS-TMPRSS6-LRx Dose Level 2</arm_group_label>
    <other_name>ISIS 702843</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Meet modified World Health Organization (WHO) 2016 diagnostic criteria for&#xD;
             polycythemia vera (PV) at the time of clinical diagnosis&#xD;
&#xD;
          2. Participant must be phlebotomy dependent&#xD;
&#xD;
          3. The participant's cytoreductive therapy must either be discontinued at least 3 months&#xD;
             prior to Screening, OR participant must be on a stable dose for at least 3 months&#xD;
             prior to Screening&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Meets criteria for post-polycythemia vera myelofibrosis (PPV-MF) as defined by the&#xD;
             International Working Group- Myeloproliferative Neoplasms Research and Treatment&#xD;
             (IWG-MRT)&#xD;
&#xD;
          2. Moderate to severe splenic pain or spleen-related organ obstruction&#xD;
&#xD;
          3. Active or chronic bleeding within 1 month of Screening, significant concurrent/recent&#xD;
             coagulopathy, history of immune thrombocytopenic purpura (ITP)&#xD;
&#xD;
          4. Known primary or secondary immunodeficiency&#xD;
&#xD;
          5. Active infection with human immunodeficiency virus (HIV), hepatitis C, or hepatitis B.&#xD;
&#xD;
          6. Active infection requiring systemic antiviral or antimicrobial therapy or active novel&#xD;
             coronavirus disease (Covid-19) infection&#xD;
&#xD;
          7. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or&#xD;
             carcinoma in situ of the cervix or non-metastatic prostate cancer that has been&#xD;
             successfully treated&#xD;
&#xD;
          8. Surgery requiring general anesthesia within 1 month prior to Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>800-679-4747</phone>
    <email>patients@ionisph.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 20, 2021</last_update_submitted>
  <last_update_submitted_qc>November 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-PV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

